S. Din

发表

Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease–Associated Colorectal Cancers

Martin L. Miller, J. Satsangi, D. Adams, 2018, Clinical Cancer Research.

Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.

C. Lees, P. Brennan, C. Mowat, 2019, Journal of Crohn's & colitis.

Combination therapy of infliximab and azathioprine reduces disease progression in Crohn's disease.

J. Satsangi, I. Arnott, C. Noble, 2008, Inflammatory bowel diseases.

Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel

C. Lees, A. Hart, C. Lamb, 2020, Gut.

Immunotherapy-induced coeliac disease in curative lung cancer

A. Shand, S. Din, H. Walton, 2021, BMJ Case Reports.

Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study

Philip Smith, C. Lees, N. Bhala, 2021, The Lancet Gastroenterology & Hepatology.

c-MET immunohistochemical expression in sporadic and inflammatory bowel disease associated lesions

M. Arends, R. Porter, S. Din, 2022, World journal of gastroenterology.

Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic

C. Lees, N. Bhala, C. Lamb, 2020, Frontline Gastroenterology.

IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology

C. Lees, P. Henderson, I. Arnott, 2019, Gut.

Managing IBD in patients with previous cancers

S. Din, Sarah E. Minnis-Lyons, S. Chow, 2022, Frontline Gastroenterology.

Implementation of CT-P13 via a Managed Switch Programme in Crohn’s Disease: 12-Month Real-World Outcomes

C. Lees, I. Arnott, G. Ho, 2018, Digestive Diseases and Sciences.

Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic

C. Lamb, G. Moran, D. Gaya, 2021, Frontline Gastroenterology.

Use of methotrexate in refractory Crohn's disease: The Edinburgh experience

J. Satsangi, I. Arnott, A. Shand, 2008, Inflammatory Bowel Diseases.

Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity

C. Lees, T. Ahmad, C. Lamb, 2022, Gut.

Profound diarrhoea and weight loss in an immunocompromised patient

I. Arnott, A. Shand, S. Din, 2021, BMJ Case Reports.

Towards a clinically-based common coordinate framework for the human gut cell atlas: the gut models

R. Baldock, D. Adams, A. Burger, 2022, bioRxiv.

Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme

B. Ramsahoye, D. Jodrell, S. Din, 2010, Nucleic acids research.

Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines

M. Arends, R. Porter, S. Din, 2021, Journal of Crohn's & colitis.

Systematic review with network meta‐analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease

C. Black, C. Selinger, A. Ford, 2022, Alimentary pharmacology & therapeutics.

PTU-002 Achieving biochemical remission in crohn’s disease with adalimumab therapy utilsing therapeutic drug monitoring

C. Lees, I. Arnott, C. Noble, 2018, IBD.

Technology Insight: the application of proteomics in gastrointestinal disease

J. Satsangi, A. Lennon, T. Hupp, 2007, Nature Clinical Practice Gastroenterology &Hepatology.

SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement

M. Parkes, C. Lees, T. Ahmad, 2021, The Lancet Gastroenterology & Hepatology.

Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease

A. Seicean, C. Iuga, R. Seicean, 2021, Journal of personalized medicine.

Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission.

C. Lees, I. Arnott, G. Ho, 2018, Inflammatory bowel diseases.

COVID-19: Colorectal cancer endoscopic surveillance in IBD

D. Gaya, I. Arnott, S. Din, 2021, The Lancet Gastroenterology & Hepatology.

British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance

C. Lamb, C. Selinger, I. Penman, 2022, Gut.

The Promise of Single-Cell RNA Sequencing to Redefine the Understanding of Crohn’s Disease Fibrosis Mechanisms

R. Baldock, D. Adams, A. Burger, 2023, Journal of clinical medicine.

A Roadmap for the Human Gut Cell Atlas

Lori A. Coburn, A. Regev, R. Xavier, 2023, Nature Reviews Gastroenterology & Hepatology.

Establishment of a validated central reading system for ileocolonoscopy in an academic setting

M. Parkes, S. Travis, N. Kennedy, 2022, Gut.

BSG 2024 IBD guidelines protocol (standard operating procedures)

Philip Smith, G. Moran, J. Limdi, 2023, BMJ open gastroenterology.

QuPath Algorithm Accurately Identifies MLH1-Deficient Inflammatory Bowel Disease-Associated Colorectal Cancers in a Tissue Microarray

P. Bankhead, A. Oniscu, M. Arends, 2023, Diagnostics.

Autologous stem cell transplantation in refractory Crohn’s disease – low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study

R. Emsley, M. Parkes, J. Satsangi, 2019, BMC Gastroenterology.

Establishing key performance indicators for inflammatory bowel disease in the UK

K. Bodger, C. Lamb, N. Kennedy, 2023, Frontline Gastroenterology.

The Comparative Pathology Workbench: Interactive visual analytics for biomedical data

R. Baldock, A. Burger, I. Papatheodorou, 2023, Journal of Pathology Informatics.

Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease–Associated Colorectal Cancers

Martin L. Miller, J. Satsangi, D. Adams, 2018, Clinical Cancer Research.